Living with CML can be challenging. Fortunately, these advances in CML treatment offer hope beyond daily pills.

Panelists discuss how medication adherence significantly impacts chronic myeloid leukemia (CML) treatment outcomes, with research showing even small differences between 90% and 95% adherence to ...

As the luminary ceremony began and candlelit bags glowed in the dark, each carrying the name of a loved one, Zach felt ...

The Radich laboratory was one of the first to document that monitoring levels of the abnormal, CML-promoting “BCR-ABL” fusion protein can be used to detect “minimal residual disease” and predict ...

First-in-class STAMP inhibitor Scemblix (asciminib) is already starting to see sales ramp up as a third-line or later therapy for CML – an indication approved by the FDA in 2021 – with a third ...